Darbepoetin Alfa

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Darbepoetin Alfa
   1. Pharmacist Assessment Report
   2. Darbepoetin Alfa: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Darbepoetin Alfa: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Darbepoetin Alfa, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
chronic kidney failure	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
5637Q	Aranesp	Injection 10 micrograms in 0.4 mL pre-fi	Valid

Safety Considerations

• Contraindications (knowledge graph, not label text): The TxGNN knowledge graph links the drug to hypertensive disorder and hypertension as contraindication-related conditions.
• Drug Interactions (17 recorded):
  • Major: carfilzomib, lenalidomide, pomalidomide, thalidomide
  • Moderate: cyclosporine, human C1-esterase inhibitor, conestat alfa
  • Minor: ACE inhibitors (fosinopril, benazepril, captopril, enalapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)
• Other concerns noted in the data: ESAs carry safety concerns about tumour progression and mortality in some cancer settings, and hypersensitivity reactions are possible with protein therapeutics.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---